![CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6604904/MediaObjects/41416_2009_Article_BF6604904_Fig1_HTML.jpg)
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
![Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer | SpringerLink Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-013-0050-3/MediaObjects/12325_2013_50_Fig1_HTML.gif)
Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer | SpringerLink
Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice
Mechanism of action of abiraterone and antiandrogens. Abbreviations: A,... | Download Scientific Diagram
![Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born - Michael T. Schweizer, Emmanuel S. Antonarakis, 2012 Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born - Michael T. Schweizer, Emmanuel S. Antonarakis, 2012](https://journals.sagepub.com/cms/10.1177/1756287212452196/asset/images/large/10.1177_1756287212452196-fig2.jpeg)
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born - Michael T. Schweizer, Emmanuel S. Antonarakis, 2012
![AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD](https://www.urotoday.com/images/stories/conferences/aua_2012/moul_slide2.jpg)
AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD
![Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice](https://www.mdpi.com/cancers/cancers-13-03518/article_deploy/html/images/cancers-13-03518-g001.png)
Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
![Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial - The Lancet Oncology Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/55cededf-1f05-49ef-a0b7-4f7265b426fc/gr1.jpg)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial - The Lancet Oncology
![2011 Prostate Cancer Highlights, Prostate Cancer Research Program, Congressionally Directed Medical Research Programs 2011 Prostate Cancer Highlights, Prostate Cancer Research Program, Congressionally Directed Medical Research Programs](https://cdmrp.health.mil/images/misc/wilding_figure.jpg)
2011 Prostate Cancer Highlights, Prostate Cancer Research Program, Congressionally Directed Medical Research Programs
![Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer](https://www.frontiersin.org/files/MyHome%20Article%20Library/477083/477083_Thumb_400.jpg)
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
![Cancers | Free Full-Text | Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on Cancers | Free Full-Text | Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on](https://pub.mdpi-res.com/cancers/cancers-13-00509/article_deploy/html/images/cancers-13-00509-ag.png?1611907475)
Cancers | Free Full-Text | Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
![Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 ... Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 ...](http://www.oncoprescribe.com/app/uploads/_1423058163.jpg)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 ...
![Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma Nandha R - J Postgrad Med Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma Nandha R - J Postgrad Med](https://www.jpgmonline.com/articles/2012/58/3/images/jpgm_2012_58_3_203_101400_f2.jpg)